LEI

Cairn Homes Plc: Holding(s) in Company

Retrieved on: 
Wednesday, March 13, 2024

In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

Key Points: 
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    3% threshold crossed upwards by Financial instruments.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).

Cairn Homes Plc: Holding(s) in Company

Retrieved on: 
Wednesday, March 13, 2024

The Emerald Opportunity Investment Fund, a sub fund of The Emerald Fund ICAV, is the sole limited partner and economic beneficiary of Emerald Everleigh Limited Partnership.

Key Points: 
  • The Emerald Opportunity Investment Fund, a sub fund of The Emerald Fund ICAV, is the sole limited partner and economic beneficiary of Emerald Everleigh Limited Partnership.
  • Emerald Everleigh Limited Partnership utilises the services of Goodbody Stockbrokers Nominees Limited as nominee, which holds 6,743,507 voting rights (1.04%) of the issuer.
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    i.
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.

Cairn Homes Plc: Holding(s) in Company

Retrieved on: 
Wednesday, March 13, 2024

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.

Key Points: 
  • iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
  • As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
  • v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC).
  • xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

Cairn Homes Plc: Holding(s) in Company

Retrieved on: 
Wednesday, March 13, 2024

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:

Key Points: 
  • financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:
    PM Capital Global Companies Fund (LEI: 549300G9AAH2W5NCIP82)
    PM Capital Enhanced Yield Fund (LEI: 549300HZRCOLTKE3LT85)
    PM Capital Global Long Fund (LEI: 549300JRD4CV9FOK2S31)
    PM Capital Global Opportunities Fund Ltd (LEI: 5493002RXP07KPHL2B32)
    Colonial First State Investments Ltd (ACN 002 348 352) as trustee for Commonwealth Specialist Fund 11 (LEI: 5493005W2U5Q75KEGB51)
    Colonial First State Investments Ltd (ACN 002 348 352) as trustee for Commonwealth Fixed Interest Fund 11 (LEI: 549300J04EXUIXPVSV26)
    11.
  • In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]
    Done at Sydney, Australia on 23 February 2024.
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Retrieved on: 
Monday, March 11, 2024

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance.
  • This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial.
  • Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F.
  • This reinforces our enthusiasm for developing izokibep as an important potential new medicine for patients.”

STMicroelectronics Announces Status of Common Share Repurchase Program

Retrieved on: 
Monday, March 11, 2024

AMSTERDAM – March 11, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021. The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.

Key Points: 
  • Disclosure of Transactions in Own Shares – Period from Mar 04, 2024 to Mar 08, 2024
    AMSTERDAM – March 11, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021.
  • The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.
  • The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from debt financial instruments that are exchangeable into equity instruments.
  • Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

STMicroelectronics Announces Status of Common Share Repurchase Program

Retrieved on: 
Monday, March 4, 2024

AMSTERDAM – March 4, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021. The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.

Key Points: 
  • Disclosure of Transactions in Own Shares – Period from Feb 26, 2024 to Mar 01, 2024
    AMSTERDAM – March 4, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021.
  • The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.
  • The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from debt financial instruments that are exchangeable into equity instruments.
  • Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

STMicroelectronics Announces Status of Common Share Repurchase Program

Retrieved on: 
Monday, February 26, 2024

AMSTERDAM – February 26, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021. The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.

Key Points: 
  • Disclosure of Transactions in Own Shares – Period from Feb 20, 2024 to Feb 23, 2024
    AMSTERDAM – February 26, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021.
  • The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.
  • The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from debt financial instruments that are exchangeable into equity instruments.
  • Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

STMicroelectronics Announces Status of Common Share Repurchase Program

Retrieved on: 
Monday, February 19, 2024

AMSTERDAM – February 19, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021. The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.

Key Points: 
  • Disclosure of Transactions in Own Shares – Period from Feb 12, 2024 to Feb 16, 2024
    AMSTERDAM – February 19, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021.
  • The Program was approved by a shareholder resolution dated May 27, 2021 and by the supervisory board.
  • The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from debt financial instruments that are exchangeable into equity instruments.
  • Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

Finance: InfoCamere lands in the UK with 'ID-LEI' service

Retrieved on: 
Monday, March 4, 2024

LONDON, March 4, 2024 /PRNewswire/ -- Reliability, flexibility and speed to move confidently between financial instruments. InfoCamere - company of Italian Chambers of Commerce for digital innovation and leader for reliability in registration and information services for businesses - has extended its activity in Europe for the issuing and management of LEI-Legal Entity Identifier codes (mandatory for the legal entities conducting transactions in financial instruments) through the 'ID-LEI' portal, which has just become available also in the UK.

Key Points: 
  • InfoCamere's 'ID-LEI' service is designed to simplify the process of obtaining an LEI code.
  • Thanks to a dedicated online platform companies and legal entities can apply for their LEI code quickly and easily.
  • By following the guided path offered by the ID-LEI service, the user can initiate and complete the renewal request in just a few steps.
  • A digital document, issued by InfoCamere, which proves in real time the possession of the LEI code.